1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Cuba Pharmaceuticals and Healthcare Report Q1 2017

Cuba Pharmaceuticals and Healthcare Report Q1 2017

  • November 2016
  • -
  • Business Monitor International
  • -
  • 67 pages

Includes 3 FREE quarterly updates


>BMI View:
Cuba's pharmaceuticals and healthcare sector will continue to expand over the forecast period on the back of economic growth and gradual economic liberalisation. Key market drivers will include robust growth in the medical tourism sector, the rising appeal to conduct clinical trials in the island nation and drug export growth. Over the long term, foreign pharmaceutical firms will see increased opportunities as sales expand in the local market and investment opportunities strengthen following regulatory reform.

Headline Expenditure Projections

- Pharmaceuticals: CUP1.51bn (USD1.51bn) in 2015 to CUP1.61bn (USD1.61bn) in 2016; +6.4% in local currency terms and US dollar terms. Forecast in line with last quarter.

- Healthcare: CUP11.18bn (USD11.18bn) in 2015 to CUP13.21bn (USD13.21bn) in 2016; +18.1% in local currency terms and US dollar terms. Forecast in line with last quarter. Risk/Reward Index In Q117, Cuba's Risk/Reward Index (RRI) score remains unchanged at 45.3 out of 100. Cuba is ranked 12th out of 19 countries in the Americas region in terms of market attractiveness to pharmaceutical investors according to BMI's proprietary RRI matrix. Cuba's overall score is driven by relatively high sector value growth indices and a large pensionable population, but is dragged down by a moderate market size and slow population growth.

Table Of Contents

Cuba Pharmaceuticals and Healthcare Report Q1 2017
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Cuba 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Cuba 2012-2020) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Cuba 2012-2020) 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Cuba 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Cuba 2012-2020) 18
Pharmaceutical Trade Forecast 18
Table: Pharmaceutical Trade Data And Forecasts (Cuba 2014-2020) 21
Industry Risk/Reward Index 22
Americas Risk/Reward Index 22
Cuba Risk/Reward Index 27
Rewards 27
Risk 27
Regulatory Review 29
Intellectual Property Issues 31
Pricing Regime 32
Reimbursement Regime 32
Market Overview 34
Healthcare Sector 35
Table: Healthcare Resources (Cuba 2010-2015) 36
Table: Healthcare Personnel (Cuba 2010-2015) 37
Table: Healthcare Activity (Cuba 2010-2015) 37
Research and Development 37
Clinical Trials 39
Epidemiology 40
Competitive Landscape 43
Research-Based Industry 43
Table: Biotechnology, Pharmaceutical and Healthcare's Members of CAMARACUBA, 2010 44
Table: Licensed Local Pharmaceutical Producers, April 2011 46
Table: Foreign Producers with GMP Certificates, April 2011 52
Generic Drugmakers 54
Pharmaceutical Distribution 55
Pharmaceutical Retail Sector 55
Demographic Forecast 56
Table: Population Headline Indicators (Cuba 1990-2025) 57
Table: Key Population Ratios (Cuba 1990-2025) 57
Table: Urban/Rural Population and Life Expectancy (Cuba 1990-2025) 58
Table: Population By Age Group (Cuba 1990-2025) 58
Table: Population By Age Group % (Cuba 1990-2025) 59
Glossary 61
Methodology 63
Pharmaceutical Expenditure Forecast Model 63
Healthcare Expenditure Forecast Model 63
Notes On Methodology 64
Risk/Reward Index Methodology 65
Index Overview 66
Table: Pharmaceutical Risk/Reward Index Indicators 66
Indicator Weightings 67

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.